US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.3190

+0.00150.47%

Post-market: 0.3100-0.0090-2.82%18:57 EDT

Volume:9.50K

Turnover:2.98K

Market Cap:6.48M

PE:4.17

High:0.3200

Open:0.3010

Low:0.3010

Close:0.3175

Loading ...

Overview Company News Filings

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

AECOM reports fourth quarter and full year fiscal 2024 results

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

Valero Energy Corp (NYSE:VLO): A Bullish Investment Perspective

Press Release: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Press Release: QT Imaging Announces Third Quarter 2024 Financial Results

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Coinbase launches COIN50 Index to track digital assets

Shell welcomes Dutch Court of Appeal ruling

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCI/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":0.319,"timestamp":1746648000000,"preClose":0.3175,"halted":0,"volume":9500,"hourTrading":{"tag":"盘后","latestPrice":0.31,"preClose":0.319,"latestTime":"18:57 EDT","volume":228,"amount":70.68,"timestamp":1746658621489},"delay":0,"floatShares":1726200,"shares":20320000,"eps":0.076408,"marketStatus":"Not Yet Opened","change":0.0015,"latestTime":"05-07 16:00:00 EDT","open":0.301,"high":0.32,"low":0.301,"amount":2977.8008400000003,"amplitude":0.059843,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.076408,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746691200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":0.3175,"dividendRate":0.626959,"preHourTrading":{"tag":"盘前","latestPrice":0.32,"preClose":0.32,"latestTime":"08:00 EDT","volume":164,"amount":52.480000000000004,"timestamp":1746619207661},"postHourTrading":{"tag":"盘后","latestPrice":0.31,"preClose":0.319,"latestTime":"18:57 EDT","volume":228,"amount":70.68,"timestamp":1746658621489},"volumeRatio":0.201865},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":1726200,"roa":"6.28%","roe":"58.31%","lyrEps":0.031396,"volumeRatio":0.201865,"shares":20320000,"dividePrice":0.2,"high":0.32,"amplitude":0.059843,"preClose":0.3175,"low":0.301,"week52Low":0.28,"pbRate":"1.01","psRate":"0.29","week52High":1.8,"institutionHeld":0.7857,"latestPrice":0.319,"eps":0.076408,"divideRate":0.626959,"volume":9500,"delay":0,"ttmEps":0.076408,"open":0.301,"prevYearClose":0.66,"prevWeekClose":0.3101,"prevMonthClose":0.3446,"prevQuarterClose":0.48,"fiveDayClose":0.3446,"twentyDayClose":0.4399,"sixtyDayClose":0.5201},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2486855110","title":"Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486855110","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486855110?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:30","pubTimestamp":1732537800,"startTime":"0","endTime":"0","summary":"Single intrathecal dose of Rhenium (186Re) Obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (LM) patients Achieves up to 8x absorbed radiation dose t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/25/2986577/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Phase-1-Interim-Data-for-Leptomeningeal-Metastases-at-the-2024-SNO-Annual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4202","BK4139","LENZ","CSF"],"gpt_icon":0},{"id":"2485498812","title":"Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2485498812","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485498812?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:30","pubTimestamp":1732192200,"startTime":"0","endTime":"0","summary":"CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985113/0/en/Plus-Therapeutics-to-Present-Multi-Institutional-Experience-Using-the-CNSide-Cerebrospinal-Fluid-Assay-in-Patients-with-Leptomeningeal-Metastases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4202","CSF","NGS","BK4179","LENZ","BK4139"],"gpt_icon":0},{"id":"2484981895","title":"AECOM reports fourth quarter and full year fiscal 2024 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2484981895","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484981895?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"Fiscal 2025 guidance includes record net service revenue, margins and earnings. Increased the share repurchase authorization to $1 billion and the quarterly dividend by 18%. DALLAS, November 18, 2024----AECOM , the trusted global infrastructure leader, today reported fourth quarter and full year fiscal 2024 results.Fourth Quarter and Full Year Fiscal 2024 Highlights:. Fourth quarter adjusted1 EBITDA4 and adjusted1 EPS increased by 15% and 26%, respectively.For the full year, adjusted1 EBTDA4 and adjusted1 EPS increased 14% and 22%, respectively.The adjusted EBITDA margin5 was 16.7% in the fourth quarter and 16.0% for the full year, reflecting an increase of 140 basis points and 100 basis points, respectively.The segment adjusted1 operating margin3 was 16.7% in the fourth quarter; for the full year, the margin was 15.8%, which exceeded guidance of 15.6%.Design book-to-burn8 in the fourth quarter was 1.2x, including 1.2x in both the Americas and International s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aecom-reports-fourth-quarter-full-210500752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4516","BK4202","BK4129","ACM","NSR","LU2308191902.HKD"],"gpt_icon":0},{"id":"2484622807","title":"Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622807","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622807?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"- Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes. - Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025. - Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed or refractory acute myeloid leukemia. - Accomplished biopharma industry executive June Almenoff, M.D., Ph.D., appointed to Actinium's Board of Directors. - Cash and cash equivalents of approximately $78.6 million as of September 30, 2024, is expected to fund operations into 2027. Sandesh Seth, Actinium's Chairman and CEO, stated, \"During the third quarter and over the last several weeks, we have made significant progress with ou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/57avoh2.1orfF.ef8KKSbQ--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/57avoh2.1orfF.ef8KKSbQ--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-highlights-antibody-radiation-130000950.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-highlights-antibody-radiation-130000950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","BK4229","NCI","BK4139","BK4195","ACT","ATNM"],"gpt_icon":0},{"id":"2483124725","title":"Valero Energy Corp (NYSE:VLO): A Bullish Investment Perspective","url":"https://stock-news.laohu8.com/highlight/detail?id=2483124725","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483124725?lang=en_us&edition=fundamental","pubTime":"2024-11-16 22:56","pubTimestamp":1731769000,"startTime":"0","endTime":"0","summary":"We came across abullish thesis onValero Energy Corp  on ValueInvestorsClub by Alejo Velez. In this article, we will summarize the bulls’ thesis on VLO. VLO’s stock was trading at $151 when this thesis was published, vs. a closing price of $137.02 on November 12.VLO is one of the dominant leaders in the global refining industry which comprises complex refineries in the United States and the United Kingdom. With time, VLO has posted high returns despite the volatility of the oil industry. The company has been compounding at 15.5% annually since its IPO in 1997 and its dividend has grown by 15%, helping shareholders even through downturns.Recently, the energy sector’s transition to electric vehicles  threatens to reduce oil demand, with an expected decrease of 30-50% by 2050. Although this has its demerits, VLO has been able to adapt by taking advantage of the growing scarcity of refining capacity around the world.READ NEXT:8 Best Wide Moat Stocks to Buy Nowand30 Most Important AI Stocks ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EzVuSeww9h7W33JqaIs50w--~B/aD02MzA7dz05NzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/30d4f1a00a7ea790808c59580d3a24cb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EzVuSeww9h7W33JqaIs50w--~B/aD02MzA7dz05NzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/30d4f1a00a7ea790808c59580d3a24cb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valero-energy-corp-nyse-vlo-145640797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0300736492.USD","LU0345780950.USD","LU0368265418.SGD","BK4585","NCI","IE00B2Q91V27.USD","LU0630314457.HKD","LU0788109394.HKD","NYSE","LU0122376428.USD","BK4588","LU0266512127.USD","IE00BSNM7G36.USD","IE00BGHQF524.EUR","IE00B3CCJ963.GBP","BK4138","VLO","BK4202","SG9999001440.SGD","LU0456854461.SGD","LU0345781412.USD"],"gpt_icon":0},{"id":"2483868077","title":"Press Release: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868077","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868077?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:15","pubTimestamp":1731532500,"startTime":"0","endTime":"0","summary":"-- Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia  Remains on Track for Q4 2024 --. -- GPS Granted FDA Rare Pediatric Disease Designation  for the Treatment of Pediatric AML --. NEW YORK, Nov. 13, 2024  -- SELLAS Life Sciences Group, Inc.  , a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.Phase 3 REGAL study in AML: In June, the IDMC conducted a prespecified risk-benefit assessment of unblinded data from the study and recommended that the trial continue without modifications. Based on a detailed analysis of all unblinded data, the IDMC projected that the interim analysis  will occur in the fourth quarter of 2024.Granted FDA Rare Pediatric Disease Designation : The FDA granted Rare Pediatric Disease Designation  to GPS for the","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","SLS","BK4109","BK4202","BK4139","ASH","LU2463526074.USD"],"gpt_icon":1},{"id":"2483100044","title":"Press Release: QT Imaging Announces Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483100044","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483100044?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:32","pubTimestamp":1731504720,"startTime":"0","endTime":"0","summary":"Generated Scanner Sales Revenue of $0.9 Million with 65% Gross Margin in the Third Quarter of 2024. The Company Successfully Completed the Engineering and Clinical Feasibility Study with its Strategic Partner. The Company Announced Entering into Favorable Amendments to Its $10 Million Convertible Promissory Note with YA II PN, Ltd.\"During this quarter, QT Imaging's team successfully completed the engineering and clinical feasibility study with our strategic partner and shipped two QT Breast Acoustic CT Scanners to a nationally recognized clinical site and to a functional medicine clinic in Illinois, together with our distribution partner, NXC Imaging. The third-year renewal of our five-year research grant from the National Institutes of Health /National Cancer Institute  was signed during the quarter,\" said Dr. Raluca Dinu, QT Imaging Chief Executive Officer.During this quarter, QT Imaging successfully amended the convertible note with YA II PN, Ltd after making a payment of approximat","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","NCI","QTI","TM","BK4202","BK4082","BK4585","BK4588","03160","BK4099"],"gpt_icon":1},{"id":"2483038620","title":"Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483038620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483038620?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:30","pubTimestamp":1731497400,"startTime":"0","endTime":"0","summary":"Received tentative approval from the FDA for YUTREPIA (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/13/2980056/0/en/Liquidia-Corporation-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","BK4588","LU0211331839.USD","LU0256863811.USD","BK4532","LU0320765489.SGD","BK4580","LU1989772840.SGD","BK4161","LU0256863902.USD","BK4202","LU1989772923.USD","NCI","BK4139","BK4585","UTHR","LU0417517546.SGD","LQDA","PH","BK4007","LU0208291251.USD","LU1571399168.USD","LU1699723380.USD"],"gpt_icon":1},{"id":"2483505900","title":"Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483505900","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483505900?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:21","pubTimestamp":1731446460,"startTime":"0","endTime":"0","summary":"Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979758/0/en/Tempest-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006","NCI","BK4202"],"gpt_icon":0},{"id":"2483035762","title":"Coinbase launches COIN50 Index to track digital assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2483035762","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483035762?lang=en_us&edition=fundamental","pubTime":"2024-11-13 00:44","pubTimestamp":1731429863,"startTime":"0","endTime":"0","summary":"Crypto exchange Coinbase has introduced a new benchmark for tracking over 50 digital assets, advancing its suite of products for traders and institutional investors overseas.With the move, Coinbase is mainly targeting emerging markets and crypto-friendly jurisdictions since derivatives products tied to the index exclude major markets like the United States, the United Kingdom, and Canada.Related: Coinbase stock breaks $300 for first time since 2021. The product isn’t Coinbase’s first crypto benchmark. In 2018, the exchange launched its Coinbase Index Fund for institutional clients. The product, which required a minimum investment of $250,000, was discontinued just four months later as the company decided to focus on broader solutions to include retail users with minimum deposits as low as $25.Daily closing value of the Nasdaq Crypto Index . Source: Nasdaq. The Nasdaq also offers its own index for investors to measure the performance of a pool of digital assets. Launched in 2024, the Na","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/969e4290320d49d1a2231b85864873c5.avif","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/969e4290320d49d1a2231b85864873c5.avif"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/673385e8a539345ef77ec755/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BTC.USD.HKCC","BK4596","SOL","BTC.USD.CC","BK4202","BK4539","NCI","BK4588","RNDR.USD.HKCC","BK4112","BK4516","BK4519","BK4535","APT.USD.CC","LU1861558580.USD","TON.USD.HKCC","LU1861559042.SGD","BK4585","TON.USD.CC","APT.USD.HKCC","BK4129","BK4554","BK4595","BTC","COIN","ETH.USD.HKCC","BK4551","ETH"],"gpt_icon":1},{"id":"2482729333","title":"Shell welcomes Dutch Court of Appeal ruling","url":"https://stock-news.laohu8.com/highlight/detail?id=2482729333","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482729333?lang=en_us&edition=fundamental","pubTime":"2024-11-12 15:53","pubTimestamp":1731397980,"startTime":"0","endTime":"0","summary":"Shell plc Shell welcomes Dutch Court of Appeal ruling November 12, 2024  Today, the Court of Appeal of The Hague overturned the District Court of The Hague’s 2021 ruling in the case brought against Sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2978717/0/en/Shell-welcomes-Dutch-Court-of-Appeal-ruling.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4202"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":91,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-05-06","current":4.548188,"percent":0.070539,"low":-615.963293,"twenty":6.285272,"median":15.512604,"eighty":24.341599,"high":50.080918,"avg":6.828591,"sd":51.936132,"marketCap":6457696},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":28.783514,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":16256000},{"date":"2024-06-07","current":28.579978,"twenty":-81.702314,"median":24.992177,"eighty":34.642796,"marketCap":16154400},{"date":"2024-06-14","current":31.815689,"twenty":-79.845114,"median":25.185699,"eighty":33.392506,"marketCap":17983200},{"date":"2024-06-21","current":25.826264,"twenty":-75.704037,"median":25.951163,"eighty":31.815689,"marketCap":14610080},{"date":"2024-06-28","current":24.010495,"twenty":-75.181642,"median":25.826264,"eighty":31.166365,"marketCap":13573760},{"date":"2024-07-05","current":21.847045,"twenty":-74.134092,"median":24.992177,"eighty":30.05711,"marketCap":12350496},{"date":"2024-07-12","current":24.005484,"twenty":-72.824666,"median":24.22361,"eighty":29.406809,"marketCap":13573760},{"date":"2024-07-15","current":23.309684,"twenty":-72.571072,"median":24.010495,"eighty":29.29759,"marketCap":13183616},{"date":"2024-08-02","current":17.799213,"twenty":-72.317479,"median":24.00799,"eighty":29.18837,"marketCap":10054336},{"date":"2024-08-09","current":15.712059,"twenty":-71.040839,"median":23.456094,"eighty":28.858081,"marketCap":8900160},{"date":"2024-08-16","current":14.71315,"twenty":-69.000048,"median":23.177414,"eighty":28.661392,"marketCap":8331200},{"date":"2024-08-23","current":15.475212,"twenty":-65.359249,"median":22.360574,"eighty":28.479131,"marketCap":8761984},{"date":"2024-08-30","current":15.211668,"twenty":-16.796281,"median":21.73132,"eighty":28.375818,"marketCap":8611616},{"date":"2024-09-06","current":15.60865,"twenty":14.533412,"median":17.564477,"eighty":28.127716,"marketCap":8839200},{"date":"2024-09-13","current":18.316746,"twenty":14.714645,"median":17.091682,"eighty":27.226945,"marketCap":10363200},{"date":"2024-09-20","current":30.136472,"twenty":14.729124,"median":17.451967,"eighty":27.226945,"marketCap":17068800},{"date":"2024-09-27","current":18.155945,"twenty":14.756986,"median":17.799213,"eighty":26.316487,"marketCap":10304272},{"date":"2024-10-04","current":24.668714,"twenty":14.779837,"median":18.134605,"eighty":27.226945,"marketCap":14022832},{"date":"2024-10-11","current":19.411936,"twenty":14.800605,"median":18.316746,"eighty":26.316487,"marketCap":11029696},{"date":"2024-10-18","current":27.159393,"twenty":14.841085,"median":19.188638,"eighty":26.316487,"marketCap":15422880},{"date":"2024-10-25","current":22.801653,"twenty":14.96086,"median":20.067961,"eighty":27.538745,"marketCap":12954000},{"date":"2024-10-31","current":26.444278,"twenty":15.097424,"median":21.615595,"eighty":28.23974,"marketCap":15016480},{"date":"2024-11-08","current":25.398607,"twenty":15.188698,"median":21.880614,"eighty":27.72766,"marketCap":14427200},{"date":"2024-11-15","current":22.207911,"twenty":15.214052,"median":22.207911,"eighty":27.409251,"marketCap":12598400},{"date":"2024-11-22","current":20.742686,"twenty":15.227723,"median":22.212919,"eighty":27.092873,"marketCap":11765280},{"date":"2024-11-29","current":19.71984,"twenty":15.244259,"median":22.031838,"eighty":26.826792,"marketCap":11184128},{"date":"2024-12-06","current":19.342155,"twenty":15.419442,"median":21.847045,"eighty":26.825987,"marketCap":10972800},{"date":"2024-12-13","current":18.931587,"twenty":15.475212,"median":20.935809,"eighty":26.444278,"marketCap":10749280},{"date":"2024-12-20","current":16.81288,"twenty":15.549996,"median":20.067961,"eighty":26.379894,"marketCap":9550400},{"date":"2024-12-27","current":7.581302,"twenty":15.240125,"median":20.023482,"eighty":26.25308,"marketCap":10741152},{"date":"2025-01-03","current":8.618162,"twenty":15.140189,"median":19.71984,"eighty":26.21899,"marketCap":12196064},{"date":"2025-01-10","current":10.05795,"twenty":14.800605,"median":19.685908,"eighty":26.181452,"marketCap":14224000},{"date":"2025-01-17","current":8.786233,"twenty":14.714645,"median":19.468094,"eighty":26.125394,"marketCap":12415520},{"date":"2025-01-24","current":9.780279,"twenty":10.25185,"median":19.354401,"eighty":26.087984,"marketCap":13817600},{"date":"2025-01-31","current":8.55813,"twenty":9.931507,"median":18.990258,"eighty":25.926183,"marketCap":12088368},{"date":"2025-02-07","current":8.034161,"twenty":9.67709,"median":18.942456,"eighty":25.806345,"marketCap":11354816},{"date":"2025-02-14","current":7.429972,"twenty":9.170381,"median":18.736365,"eighty":25.661057,"marketCap":10499344},{"date":"2025-02-21","current":7.182682,"twenty":8.786233,"median":18.611629,"eighty":25.398607,"marketCap":10166096},{"date":"2025-02-28","current":6.088957,"twenty":8.49005,"median":18.298903,"eighty":25.263582,"marketCap":8617712},{"date":"2025-03-07","current":6.285152,"twenty":8.101774,"median":18.113266,"eighty":25.252549,"marketCap":8900160},{"date":"2025-03-14","current":5.596631,"twenty":7.768683,"median":17.68941,"eighty":25.185699,"marketCap":7924800},{"date":"2025-03-21","current":6.28575,"twenty":7.480228,"median":17.54621,"eighty":25.06182,"marketCap":8900160},{"date":"2025-03-28","current":6.3175,"twenty":7.319362,"median":17.202773,"eighty":24.992177,"marketCap":8940800},{"date":"2025-04-04","current":6.433722,"twenty":7.066391,"median":16.81288,"eighty":24.761928,"marketCap":9104010},{"date":"2025-04-11","current":7.43656,"twenty":6.901399,"median":16.523806,"eighty":24.668714,"marketCap":10546080},{"date":"2025-04-17","current":5.733501,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"marketCap":8128000},{"date":"2025-04-25","current":5.587097,"twenty":6.410478,"median":15.712059,"eighty":24.4461,"marketCap":7924800},{"date":"2025-05-02","current":4.29948,"twenty":6.295892,"median":15.579323,"eighty":24.363962,"marketCap":6100064},{"date":"2025-05-06","current":4.548188,"twenty":6.285272,"median":15.512604,"eighty":24.341599,"marketCap":6457696}],"updateTime":1746684510873}}}